Lipid disorders: Justification of methods and goals of treatment

Chest

Volumn 120, Issue 3, 2001, Pages 979-988

  Braunstein, Joel B ^a   Cheng, Alan ^a   Cohn, Gregory ^b   Aggarwal, Monica ^c   Nass, Caitlin M ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular risk factors; Coronary heart disease; Dyslipidemia; Hypercholesterolemia; Lipid lowering agents; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MORTALITY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034820571     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.3.979     Document Type: Review

References (60)

1. Lipids risk of coronary heart disease: The Framingham Study
2. The antiatherogenic role of high-density lipoprotein cholesterol
3. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
4. Epidemiology of triglycerides: A view from Framingham
5. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
6. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: The Cholesterol Recurrent Events Trial (CARE) investigators
10. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol recurrent events (CARE) trial
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS; Air Force/Texas Coronary Atherosclerosis Prevention Study
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
13. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
14. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
15. Incidence of coronary heart disease and lipoprotein-cholesterol levels: The Framingham Study
16. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study
17. Relation of high-density lipoprotein cholesterol triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience)
18. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
19. The association of low HDL cholesterol and arteriographically defined coronary artery disease
20. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk, factors and incidence of coronary heart disease
21. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
22. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate
23. Systematic review on the risk benefit of different cholesterol-lowering interventions
24. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
25. Cholesterol reduction yields clinical benefit: Impact of statin trials
26. Lipoprotein changes reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
27. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
28. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin Versus Revascularization Treatment (AVERT) Investigators
29. Medical therapy versus coronary angioplasty in stable coronary artery disease: A critical review of the literature
30. Lack of effect of lovastatin on restenosis after coronary angioplasty
31. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty
32. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the Fluvastatin Angiographic Restenosis Trial
33. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
34. Variations in cholesterol management practices of U.S. physicians
35. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
36. Treatment patterns distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
37. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease
38. Sex bias and under-utilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada: Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators
39. Integrated approaches to management of hypertension: Promoting treatment acceptance
40. The problem of compliance to cholesterol altering therapy
41. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease
42. Drug treatment of lipid disorders
43. Nicotinic acid for the treatment of hyperlipoproteinemia
44. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings?
45. Management of dyslipidemia in adults with diabetes
46. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines: National Cholesterol Education Program
47. Diabetes, hyperlipidemia, and coronary artery disease
48. Management of dyslipidemia in adults with diabetes
49. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
50. Hypertension as a risk factor for cardiac events: Epidemiologic results of long-term studies
51. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
52. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study
53. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
54. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
55. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart Estrogen/Progestin Replacement Study (HERS) Research Group
56. Future cardiovascular end point studies: Where will the research take us?
57. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol Recurrent Events (CARE) trial
58. Beyond the null hypothesis: Why the HERS trial did not disprove the estrogen/CHD hypothesis
59. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)